News

Conducting high-quality randomized clinical trials (RCTs) in rare diseases such as myasthenia gravis (MG) can be challenging. Researchers at Duke University and Harvard Medical School reviewed study design options that could enhance the assessment of potential new therapies for MG. The study, “Comparative effectiveness clinical…

Researchers report that two autoantibodies found in patients with myasthenia gravis (MG) may cause the disease in a subgroup of patients. These autoantibodies might also serve as biomarkers, indicating that MG is a complex disease with different causes. The review article, titled “Agrin and LRP4 antibodies as new…

The Myasthenia Gravis Foundation of America brought together a group of experts with the aim of establishing a formal consensus statement for the treatment and care of patients with myasthenia gravis (MG). An overview on the proposed guidelines was recently published in the article, “Developing treatment…

Biological agents that target inflammation-generating immune cells and signaling molecules could be used to treat myasthenia gravis, French researchers report. Biologics have helped people with other autoimmune diseases, so they might be able to restore balance to MG patients’ immune system, the team said. MG stems from an imbalance between…

This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…

Combining a traditional Chinese medicine known as Qi supplement formula with conventional therapy shows short-term benefits in myasthenia gravis (MG) patients, researchers in China report. But more studies of better quality are needed to support these observations, they stressed. Their study, “Efficacy and Safety of the TCM Qi-Supplementing Therapy…

Researchers in France are recruiting patients for a study to assess the effect of a moderate home-based exercise program on the quality of life and fitness of myasthenia gravis (MG) patients. The study “The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised…

Japanese researchers wrote about a myasthenia gravis (MG) patient who showed long-term improvement in disease symptoms after he was treated with blood purification therapy. The case report, “A Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic Weekly Blood Purification Therapy,” appeared in Internal Medicine, the journal…

Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy’s developer, GT Biopharma, announced. Preliminary results suggest that GTP-004 enables the safe and well-tolerated administration of…

Researchers have found that the long-term use of the immunosuppressive drug Prograf (tacrolimus) may contribute to the development of lymphoma in patients with myasthenia gravis (MG). This finding resulted from a case report published in Internal Medicine, the journal of the Japanese Society of Internal Medicine. Myasthenia gravis…